Bio-TechneNASDAQ: TECH

SCOTTSDALE, Ariz. , June 6, 2024 /PRNewswire/ -- (OTCQB: CETI), CETI has unveiled its technological breakthrough for removing insecticides, nitrates, phosphates, and cyanide from heavily contaminated agricultural, industrial and mining wastewater.

ST. PAUL, Minn. , May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene therapies (CGT).

LOS ANGELES--(BUSINESS WIRE)-- #Biotech--Molecular Instruments announced that UK Patents Court orders Advanced Cell Diagnostics to make £1.35 million costs payment to Molecular Instruments.

The latest figures for Techne (TECH) provide a glimpse into the company's performance in the first quarter of 2024, but it could be beneficial to analyze its key metrics in comparison to Wall Street projections and last year's results.

Techne (TECH) reported earnings of $0.48 per share for the quarter, exceeding the Zacks Consensus Estimate of $0.46 per share. This is lower than the earnings of $0.53 per share from the same period last year.

MINNEAPOLIS, March 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 9:45 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Techne (TECH) came out with quarterly earnings of $0.40 per share, missing the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.47 per share a year ago.

Bio-Techne's shares have fallen by a quarter since May, but the long-term thesis remains intact. The company has experienced low single-digit sales growth due to macro issues, but long-term potential is still present. Valuations have become more reasonable, making the shares more appealing, but caution is advised due to lackluster growth.